Genesis Electrical Impedance Tomography (EIT): A Preliminary Study

NCT ID: NCT03797183

Last Updated: 2025-11-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-05-03

Study Completion Date

2026-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the Genesis Electrical Impedance Tomography (EIT) imaging system for use in pediatric respiratory disease populations including neuromuscular and bronchopulmonary dysplasia, as well as in age and height matched controls. The EIT does not use radiation, and is read through electrodes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to evaluate EIT for use in pediatric respiratory disease populations including neuromuscular and bronchopulmonary dysplasia, as well as in age and height matched controls.

Researchers will use EIT to determine changes in regional ventilation with pulmonary interventions including airway clearance and invasive and noninvasive ventilation in a pediatric respiratory disease population.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Premature Infant Chronic Respiratory Disease Neuromuscular Diseases Healthy Bronchopulmonary Dysplasia Pulmonary Vein Stenoses

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Premature Infants

Premature infants \>1 month of age currently hospitalized with bronchopulmonary dysplasia (BPD) without acute respiratory infection

No interventions assigned to this group

Chronic Respiratory Disease

Participants ages \>1 month-21 years with chronic respiratory disease due to underlying neuromuscular disease

No interventions assigned to this group

Neuromuscular Disease

Participants ages 21-40 years with confirmed neuromuscular disease with an echo completed within the preceding 12 months of study participation of Duchenne muscular dystrophy (DMD) or other diagnoses associated with mild cardiomyopathy

No interventions assigned to this group

Healthy Controls

Age and height matched healthy controls

No interventions assigned to this group

V/Q Scan validation

Adults or children who are having or have recently had a V/Q scan

No interventions assigned to this group

Premature Infants (Longitudinal Cohort)

Premature infants ages 2 weeks to 1 year with diagnosed or suspected bronchopulmonary dysplasia

No interventions assigned to this group

Pulmonary Vein/Artery Stenosis

Children age 2 months to 18 years, who will be undergoing cardiac catheterization for pulmonary vein stenosis, pulmonary hypertension and/or pulmonary artery stenosis

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 2 weeks old - 40 years old
* Premature infants with current age \>2 weeks with a confirmed diagnosis of BPD based on NIH criteria
* Or Chronic respiratory disease due to underlying neuromuscular disease
* Or confirmed neuromuscular disease with an echo completed within the preceding 12 months of study participation of DMD or other diagnoses associated with mild cardiomyopathy.
* have had a VQ scan
* will be undergoing cardiac catherization for for pulmonary vein stenosis, pulmonary hypertension and/or pulmonary artery stenosis
* Or healthy controls

Exclusion Criteria

* \<2 weeks of age
* Congenital diaphragmatic hernia
* Severe congenital heart disease
* Significant genetic abnoralities
* Anything that interferes with lead placement on the chest wall
* Unwilling/refusal to sign consent
* Pregnant or lactating
* Pacemaker of other surgical implant and spinal implant (causes noise in the data)
* Moderate to severe cardiomyopathy
* Patients with temporary cognitive disability due to illness
Minimum Eligible Age

14 Days

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Colorado, Denver

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Children's Hospital Colorado

Aurora, Colorado, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Emily DeBoer, MD

Role: CONTACT

Phone: 720-777-4953

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Emily DeBoer, MD

Role: primary

Allison Keck

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

18-1843

Identifier Type: -

Identifier Source: org_study_id